COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership

Ximena A. Levander, Jarratt D. Pytell, Kenneth B. Stoller, P. Todd Korthuis, Geetanjali Chander

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In the United States, methadone for treatment of opioid use disorder is dispensed via highly-regulated accredited opioid treatment programs (OTP). During the COVID-19 pandemic, federal regulations were loosened, allowing for greater use of take-home methadone doses. We sought to understand how OTP leaders responded to these policy changes. Methods: We distributed a multistate electronic survey from September to November 2020 of OTP leadership to members of the American Association for the Treatment of Opioid Dependence (AATOD) who self-identified as leaders of OTPs. We asked study participants about how their OTP(s) implemented COVID-19-related policy changes into their clinical practice focusing on provision of take-home methadone doses, factors used to determine patient stability, and potential concerns about increased take-home doses. We used Chi-square test to compare survey responses between characterizations of the OTPs. Results: Of 170 survey respondents (17% response rate), the majority represented leadership of for-profit OTPs (69%) and were in a Southern state (54%). Routine allowances and practices related to take-home methadone doses varied across OTPs during the COVID-19 pandemic: 80 (47%) reported 14 days for newly enrolled patients (within past 90 days), 89 (52%) reported 14 days for “less stable” patients, and 112 (66%) reported 28 days for “stable” patients. Conclusions: We found that not all eligible OTP leaders adopted the practice of routinely allowing newly enrolled, “less stable,” and “stable” patients on methadone to have increased take-home doses up to the limit allowed by federal regulations during COVID-19. The pandemic provides an opportunity to critically re-evaluate long-established methadone and OTP regulations in preparation for future emergencies.

Original languageEnglish (US)
JournalSubstance Abuse
DOIs
StateAccepted/In press - 2021

Keywords

  • COVID-19
  • Methadone
  • opioid treatment programs
  • opioid-related disorders
  • survey

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership'. Together they form a unique fingerprint.

Cite this